AU2990695A - Mucin-derived proteins for the diagnosis, imaging, and therapy of human cancer - Google Patents

Mucin-derived proteins for the diagnosis, imaging, and therapy of human cancer

Info

Publication number
AU2990695A
AU2990695A AU29906/95A AU2990695A AU2990695A AU 2990695 A AU2990695 A AU 2990695A AU 29906/95 A AU29906/95 A AU 29906/95A AU 2990695 A AU2990695 A AU 2990695A AU 2990695 A AU2990695 A AU 2990695A
Authority
AU
Australia
Prior art keywords
mucin
diagnosis
therapy
imaging
human cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU29906/95A
Inventor
Daniel H Wreschner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of AU2990695A publication Critical patent/AU2990695A/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727Mucins, e.g. human intestinal mucin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015Breast
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU29906/95A 1994-07-26 1995-07-21 Mucin-derived proteins for the diagnosis, imaging, and therapy of human cancer Abandoned AU2990695A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL110464 1994-07-26
IL11046494A IL110464A0 (en) 1994-07-26 1994-07-26 Novel proteins for the diagnosis, imaging, and therapy of human cancer
PCT/IB1995/000627 WO1996003502A2 (en) 1994-07-26 1995-07-21 Muc1 derived proteins for the diagnosis, imaging and therapy of human cancer

Publications (1)

Publication Number Publication Date
AU2990695A true AU2990695A (en) 1996-02-22

Family

ID=11066387

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29906/95A Abandoned AU2990695A (en) 1994-07-26 1995-07-21 Mucin-derived proteins for the diagnosis, imaging, and therapy of human cancer

Country Status (3)

Country Link
AU (1) AU2990695A (en)
IL (1) IL110464A0 (en)
WO (1) WO1996003502A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
DE19917195B4 (en) * 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptide for triggering an immune reaction against tumor cells, pharmaceutical compositions containing them, their uses, nucleic acid coding therefor and expression vector containing said nucleic acid
AU778701B2 (en) 1999-09-08 2004-12-16 Imperial Cancer Research Technology Ltd MUC-1 derived peptides
EP1257565A4 (en) * 2000-02-01 2005-04-06 Austin Research Inst Mucin-1 derived antigens and their use in immunotherapy
EP2322929B1 (en) 2000-11-27 2016-04-06 Minerva Biotechnologies Corporation diagnostics, drug screening and treatment for cancer
AU2002246791C1 (en) 2000-12-22 2008-04-03 Dana-Farber Cancer Institute, Inc. Regulation of cell growth by MUC1
EP1578345A2 (en) * 2001-03-29 2005-09-28 RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. Peptides and antibodies to muc 1 proteins
US7183388B2 (en) 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
CA2443138A1 (en) * 2001-03-30 2002-10-10 The Regents Of The University Of California Anti-muc-1 single chain antibodies for tumor targeting
DE60225046T2 (en) * 2001-11-27 2009-07-09 Nexyte Ab PRODUCTION OF EUKARYONTIC PROTEINS AND NUCLEIC ACID MOLECULES IN C. ELEGANS
WO2003089451A2 (en) * 2002-04-22 2003-10-30 Dyax Corporation Antibodies specific for mucin polypeptide
US7202346B2 (en) 2002-07-03 2007-04-10 Immunogen Inc. Antibodies to non-shed Muc1 and Muc16, and uses thereof
GB2395270B (en) 2002-11-14 2006-08-16 Univ Nottingham Tumour marker proteins and uses thereof
EP2363410B1 (en) * 2002-11-27 2017-10-11 Minerva Biotechnologies Corporation Isoforms of MUC1
US8129506B2 (en) 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
ATE527285T1 (en) 2005-01-28 2011-10-15 Univ Ramot ANTI-MUC1 ALPHA BETA ANTIBODIES
EP1910840A2 (en) * 2005-05-26 2008-04-16 Dana-Farber Cancer Institute, Inc. Modulation of muc1-dependent anti-estrogen resistance
SI1889059T1 (en) 2005-05-27 2009-12-31 Oncimmune Ltd Improved immunoassay methods
GB2426581A (en) 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
CN101632020B (en) 2006-09-13 2013-11-27 昂西免疫有限公司 Improved immunoassay methods
US7871784B2 (en) 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
AU2016219350A1 (en) 2015-02-10 2017-08-24 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8929097D0 (en) * 1989-12-22 1990-02-28 Imp Cancer Res Tech Mucin nucleotides

Also Published As

Publication number Publication date
IL110464A0 (en) 1994-10-21
WO1996003502A3 (en) 1996-09-12
WO1996003502A2 (en) 1996-02-08

Similar Documents

Publication Publication Date Title
AU2990695A (en) Mucin-derived proteins for the diagnosis, imaging, and therapy of human cancer
HUP9902068A3 (en) Methods and compositions for the diagnosis and treatment of cancer
AU4473596A (en) Methods of human prostate cancer diagnosis
AU4349097A (en) Non-invasive imaging of biological tissue
AU3897595A (en) Skin examination device
AU4172597A (en) Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications
AU6328196A (en) Targets for breast cancer diagnosis and treatment
AU5671594A (en) Human tissue factor related dna segments, polypeptides and antibodies
AU5355094A (en) Therapeutic and diagnostic imaging compositions and methods
AU6579498A (en) Compounds and methods for the diagnosis and treatment of (ehrlichia) infection
AU2117797A (en) Medical image reconstruction only within body boundary
AU1575697A (en) Compositions and methods for the treatment and diagnosis of cancer
AU2508597A (en) Drug for the treatment of tumours
EP0831793A4 (en) Protein particles for therapeutic and diagnostic use
IL129144A0 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
AU1214995A (en) Cdna probe for breast cancer diagnosis and treatment
AU3177500A (en) Proteins for diagnosis and treatment of breast cancer
AU4953693A (en) Antibody/radioisotope conjugate for tumor diagnosis and/or therapy
AU5946999A (en) Tumour therapy and imaging
AU4841296A (en) Diagnosis of and compositions and methods for the treatment of disease
AU6653698A (en) Use of the p-ten suppressor gene in diagnosis and treatment of cancer
AU3628697A (en) Lipid-binding proteins and their therapeutic and diagnostic use
AU4068897A (en) Human induced tumor protein
AU1464399A (en) Reagent for tumor therapy and/or imaging
AU6288698A (en) Apparatus for stimulating the human body